Research programme: G protein-coupled receptor agonists - Linnaeus Therapeutics
Latest Information Update: 28 Oct 2023
At a glance
- Originator Linnaeus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Sep 2019 Preclinical trials in Cancer in USA (unspecified route)